Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice

(2012) Federica Maione et al.   JOURNAL OF CLINICAL INVESTIGATION

Semaphorin 3A Suppresses Tumor Growth and Metastasis in Mice Melanoma Model

(2012) Goutam Chakraborty et al.   PLoS One

Differential Proteomic Analysis of Human Glioblastoma and Neural Stem Cells Reveals HDGF as a Novel Angiogenic Secreted Factor

(2012) Cécile Thirant et al.   STEM CELLS

Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models

(2011) Andrea Casazza et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer

(2011) Armelle Guelte et al.   BIOLOGY OF THE CELL

Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A

(2011) J.-S. Joyal et al.   BLOOD

Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system

(2011) Gabrièle Piaton et al.   BRAIN

Stabilizing the VE-cadherin-catenin complex blocks leukocyte extravasation and vascular permeability

(2011) Dörte Schulte et al.   EMBO JOURNAL

Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway

(2011) Eva Maria Galan-Moya et al.   EMBO REPORTS

Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo

(2011) Andre Broermann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

(2011) C H Switzer et al.   ONCOGENE

CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors

(2010) Cristina Patru et al.   BMC CANCER

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

(2010) Lucia Ricci-Vitiani et al.   NATURE

Glioblastoma stem-like cells give rise to tumour endothelium

(2010) Rong Wang et al.   NATURE

Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor

(2010) J Dwyer et al.   ONCOGENE

Semaphorins and tumor angiogenesis

(2009) Guido Serini et al.   ANGIOGENESIS

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Role of Class 3 Semaphorins and Their Receptors in Tumor Growth and Angiogenesis

(2009) P. Gaur et al.   CLINICAL CANCER RESEARCH

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Autocrine semaphorin 3A signaling promotes glioblastoma dispersal

(2009) T Bagci et al.   ONCOGENE

Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor

(2008) L. M. Acevedo et al.   BLOOD

Breaking the VE-cadherin bonds

(2008) Julie Gavard   FEBS LETTERS

The FGF system has a key role in regulating vascular integrity

(2008) Masahiro Murakami et al.   JOURNAL OF CLINICAL INVESTIGATION

VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF

(2008) Astrid F. Nottebaum et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5

(2008) Andrea Taddei et al.   NATURE CELL BIOLOGY

Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player

(2008) Dietmar Vestweber et al.   TRENDS IN CELL BIOLOGY

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE